Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 2 6Phase 1 5Phase 3 3Phase NA 2Phase 2/3 2Phase 4 1

Status

Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 21INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 390Leukemia, Myeloid, Acute 371Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 326Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 302Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 234Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 211Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Epstein-Barr Virus Infections × Clear all
NCT07557602 2026-04-29

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Vaccine Company, Inc.

Phase 1 Not yet recruiting
45 enrolled

Epstein-Barr Virus Infections

NCT07478952 2026-03-24

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

ModernaTX, Inc.

Phase 1 Recruiting
120 enrolled

Epstein-Barr Virus Infections

NCT06256484 2026-03-11

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Atara Biotherapeutics

Phase 1 Terminated
1 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell

NCT05831111 2025-09-30

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

ModernaTX, Inc.

Phase 1 Active not recruiting
482 enrolled

Infections, Infectious Mononucleosis, Virus Diseases, Epstein-Barr Virus Infections

NCT06429800 2025-04-24

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Atara Biotherapeutics

Phase 1 Withdrawn

Lupus Erythematosus, Systemic, Lupus Nephritis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡